ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024

May 21, 2024

https://www.globenewswire.com/news-release/2024/05/21/2885437/0/en/ProKidney-to-Host-Virtual-KOL-Event-to-Discuss-Current-Treatment-Landscape-of-Chronic-Kidney-Disease-Caused-by-Diabetes-and-Data-from-Phase-2-RMCL-002-Clinical-Trial-on-May-28-2024.html

WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq:PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients with moderate to severe CKD caused by diabetes as well as the importance of preserving kidney function in this patient population. To register, click here.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.